San Francisco, CA (September 9, 2008). Sophion Bioscience and Scottish Biomedical announced today at the Ion Channel Targets conference that they have signed an agreement regarding ion channel cell lines. The agreement will give Sophion and Scottish Biomedical the right to provide cell lines optimized for the QPatch, Sophion’s automated patch clamp systems for the ion channel drug discovery and safety pharmacology.
“With this agreement with Sophion, we acquire a larger exposure to the market with our high quality ion channel cell lines,” said Morag Nelson, Business Development Manager at Scottish Biomedical, and she continues, “The combination of our multi-subunit cell lines and Sophion’s ability to optimize them for QPatch experiments is a very promising collaboration.”
Dr.
In the near future Sophion’s QPatch 16 and QPatch HT automated patch clamp systems can be upgraded to allow for screening of cell clones and selection of the best cell clone for propagation. This feature is expected to further improve the quality of cell lines used for ion channel drug discovery and safety pharmacology – and eventually result in more and better drugs – faster.
About Sophion Bioscience
Sophion Bioscience, a leader in the automated patch clamp field, helps drug discovery companies make more and better drugs, faster. Sophion’s sole focus is to provide advanced products and integrated solutions for automated patch clamping. Sophion’s QPatch 16 and QPatch HT (48-channels) provide high-quality patch clamp data on a truly industrial basis. Only the QPatch has an integrated cell preparation and QPlate exchange facilities enabling several hours of unattended operation. The unique microfluidic flow channel system implemented in the QPlates enables fast liquid exchange around each cell and provides the option to test multiple compounds or increasing concentrations on the same cell.
About Scottish Biomedical
Established in 1994, Scottish Biomedical is a private, pre-clinical drug discovery service organisation located on the West of Scotland Science Park in Glasgow, Scotland. Scottish Biomedical’s drug discovery business integrates ethical tissue acquisition, molecular biology, protein technology, high-throughput screening, cell biology, medicinal chemistry and pharmacology to identify and validate novel drug targets and discover and optimise lead compounds. By combining their expertise in cell systems biology with medicinal chemistry, Scottish Biomedical has established many successful drug discovery collaborations with pharmaceutical/biotech clients around the world.
For further information please contact:
page top
Join our mailinglist